| 38.83 0.69 (1.81%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.89 | 1-year : | 54.77 |
| Resists | First : | 40.15 | Second : | 46.89 |
| Pivot price | 37.9  |
|||
| Supports | First : | 35.26 | Second : | 32.25 |
| MAs | MA(5) : | 38.67  |
MA(20) : | 37.31 |
| MA(100) : | 33.15 |
MA(250) : | 33.15 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 68.3 |
D(3) : | 70.6 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 40.86 | Low : | 25.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HRMY ] has closed below upper band by 34.0%. Bollinger Bands are 31.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.15 - 39.3 | 39.3 - 39.47 |
| Low: | 37.78 - 37.94 | 37.94 - 38.13 |
| Close: | 38.53 - 38.79 | 38.79 - 39.09 |
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Mon, 17 Aug 2026
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Mon, 17 Aug 2026
Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Sun, 16 Aug 2026
Harmony Biosciences Holdings (HRMY), Why Is It Getting Fresh Attention? - simplywall.st
Sun, 16 Aug 2026
Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Fri, 14 Aug 2026
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - TradingView
Tue, 11 Aug 2026
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 100.7 (%) |
| Shares Short | 5,110 (K) |
| Shares Short P.Month | 4,650 (K) |
| EPS | 3.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.19 |
| Profit Margin | 18.8 % |
| Operating Margin | 34.1 % |
| Return on Assets (ttm) | 11.6 % |
| Return on Equity (ttm) | 20.4 % |
| Qtrly Rev. Growth | 30.2 % |
| Gross Profit (p.s.) | 12.43 |
| Sales Per Share | 16.48 |
| EBITDA (p.s.) | 4.39 |
| Qtrly Earnings Growth | 88.1 % |
| Operating Cash Flow | 355 (M) |
| Levered Free Cash Flow | 183 (M) |
| PE Ratio | 12.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 2.35 |
| Price to Cash Flow | 6.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|